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ABSTRACT
Introduction: The Depression subscale of the
Hospital Anxiety and Depression Scale (HADS-D) has
been recommended for depression screening in
medically ill patients. Many existing HADS-D studies
have used exploratory methods to select optimal cut-
offs. Often, these studies report results from a small
range of cut-off thresholds; cut-offs with more
favourable accuracy results are more likely to be
reported than others with worse accuracy estimates.
When published data are combined in meta-analyses,
selective reporting may generate biased summary
estimates. Individual patient data (IPD) meta-analyses
can address this problem by estimating accuracy with
data from all studies for all relevant cut-off scores. In
addition, a predictive algorithm can be generated to
estimate the probability that a patient has depression
based on a HADS-D score and clinical characteristics
rather than dichotomous screening classification
alone. The primary objectives of our IPD meta-
analyses are to determine the diagnostic accuracy of
the HADS-D to detect major depression among adults
across all potentially relevant cut-off scores and to
generate a predictive algorithm for individual patients.
We are already aware of over 100 eligible studies, and
more may be identified with our comprehensive
search.
Methods and analysis: Data sources will include
MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, PsycINFO and Web of Science. Eligible
studies will have datasets where patients are
assessed for major depression based on a validated
structured or semistructured clinical interview and
complete the HADS-D within 2 weeks (before or
after). Risk of bias will be assessed with the Quality
Assessment of Diagnostic Accuracy Studies-2 tool.
Bivariate random-effects meta-analysis will be
conducted for the full range of plausible cut-off
values, and a predictive algorithm for individual
patients will be generated.
Strengths and limitations of this study
▪ The study will use individual patient data to esti-
mate diagnostic accuracy for all relevant cut-off
scores of the Depression subscale of the
Hospital Anxiety and Depression Scale
(HADS-D). Using data from all patients at each
cut-off score will overcome limitations related to
selective cut-off reporting in primary study
publications.
▪ The study will conduct analyses that exclude
patients with current diagnoses of depression or
who are undergoing mental health treatment at
the time of study enrolment, as these patients
would not be screened in clinical practice. This
will overcome potential bias in primary diagnos-
tic test accuracy studies where these patients are
often included.
▪ The study will generate a predictive model to
estimate the probability that a patient with a par-
ticular HADS-D score and relevant covariates
typically available in clinical practice has depres-
sion. This will facilitate more informed clinical
decision-making than can be done with standard
diagnostic accuracy metrics.
▪ A potential limitation is that the success of the
study depends on the ability to obtain the rele-
vant individual patient data and to avoid selective
availability of studies with better or worse accur-
acy results. We do not know the proportion of
eligible datasets that will be possible to include
in the study.
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Ethics and dissemination: The findings of this study will be of
interest to stakeholders involved in research, clinical practice and
policy.
BACKGROUND
Major depressive disorder (MDD) may be present in
10–20% of patients with acute and chronic medical con-
ditions and is independently associated with poor prog-
nosis.1–6 Healthcare teams in non-psychiatric settings,
however, where the majority of depression care is pro-
vided, typically have little formal mental health training,7
and mental healthcare is often inconsistent. Many
depressed patients are not diagnosed, and a high pro-
portion of patients treated for depression do not meet
diagnostic criteria.8–12 It has been suggested that routine
screening for depression may be a solution,13 but this is
controversial.14–18
A necessary, but not sufﬁcient, condition for depres-
sion screening to beneﬁt patients is a screening tool
with demonstrated high diagnostic accuracy. In order to
correctly identify ideal cut-off screening thresholds and
to obtain unbiased diagnostic accuracy estimates, several
major problems common to studies of depression
screening tools must be addressed. These include (1)
the overreliance on primary studies with small sample
sizes that selectively report results from only well-
performing cut-off thresholds;19 20 (2) the inclusion in
primary studies of patients already being treated for
depression, even though these patients are not screened
in actual practice, since screening is done to detect
unrecognised cases;21 22 and (3) the lack of consider-
ation of individual patient depression risk factors (eg,
age, sex, inpatient vs outpatient care) in estimates of
screening accuracy.23
The Depression subscale of the Hospital Anxiety and
Depression Scale (HADS-D) is the most commonly used
screening tool in medically ill patients.24–26 Most existing
studies of the accuracy of the HADS-D have (1) been
conducted in samples too small to precisely estimate
accuracy, (2) included already-diagnosed and treated
patients and (3) selectively published accuracy results
from cut-offs that perform well, but not other relevant
cut-offs.25 27–29 For instance, in one meta-analysis of the
diagnostic accuracy of the HADS-D,27 the authors
excluded 16 of 41 (39%) primary studies that examined
the diagnostic accuracy of the HADS because those
studies only reported results from study-speciﬁc optimal
cut-offs, but not from standard cut-offs, which were
pooled in the meta-analysis. The inability to include
studies that did not publish more pessimistic results asso-
ciated with standard HADS cut-offs likely led to inﬂated
estimates of accuracy in the meta-analysis compared to
real-world performance using standard cut-offs. In other
meta-analyses,25 28 29 authors have reported results from
a single bivariate accuracy model that included results
from different cut-offs from different primary studies,
sometimes from the best-performing sample-speciﬁc
cut-off in each study.
Individual patient data (IPD) meta-analysis can poten-
tially address some of these problems. IPD meta-analysis
involves using actual patient data obtained from
researchers who conducted primary studies, rather than
summary results from published or unpublished study
reports.30 The steps involved in conducting a systematic
review with an IPD meta-analysis, in terms of deﬁning a
research question, establishing study inclusion and exclu-
sion criteria, identifying and screening studies and ana-
lysing data, are similar to those in a traditional systematic
review and meta-analysis and diverge only in analysing
individual-level data rather than summary data.31 In the
context of evaluating the diagnostic accuracy of depres-
sion screening tools, IPD meta-analysis has a number of
potential advantages compared with a conventional
meta-analysis. First, it can address bias from the selective
reporting in publications of only well-performing cut-off
thresholds since accuracy can be evaluated across all
relevant cut-off scores. Second, it allows the systematic
exclusion of already-treated patients, for whom the tool
would not be used to screen for unidentiﬁed depression.
Third, IPD meta-analysis with large numbers of patients
and large numbers of depression cases allows the incorp-
oration of study variables (eg, study setting, risk of bias
factors) and individual factors that may inﬂuence screen-
ing accuracy (eg, age, sex, inpatient vs outpatient). In
addition, a large IPD database allows the development of
a predictive algorithm to generate estimates of the prob-
ability of having depression based on patient character-
istics and actual HADS-D scores, rather than classifying
patients as simply negative or positive based on screen-
ing results. This is an important consideration because a
patient with a score of 0 on the HADS-D, for example,
would almost certainly have a lower likelihood of having
depression than a patient with a substantially higher, but
subthreshold, score of 7, although typically both would
be classiﬁed as negative screens.
A potential downside of IPD meta-analyses is that they
are resource intensive. Furthermore, they can be biased
if the primary datasets obtained are not representa-
tive.30–33 Currently, our team is conducting an IPD
meta-analysis of the Patient Health Questionnaire
depression screening tool, which is the ﬁrst IPD
meta-analysis of the diagnostic accuracy of a depression
screening tool.34 In that study, which is still in progress
as of 14 March 2016, we had veriﬁed 76 eligible primary
datasets and obtained usable data for 60 of them. This
suggests that investigators are generally able and willing
to provide primary data from studies of the diagnostic
accuracy of depression screening tools for use in IPD
meta-analyses. On the basis of preliminary searches, we
are aware of at least 100 eligible studies on the HADS-D.
Thus, the objectives of this IPD meta-analysis are to
determine the diagnostic accuracy of the HADS-D to
detect major depression among patients in medical set-
tings and to develop an algorithm to predict the
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probability that individual patients have MDD based on
HADS-D scores and patient characteristics.
METHODS AND ANALYSIS
This systematic review has been funded by the Canadian
Institutes of Health Research (Funding Reference
Number KRS-144045). The protocol has been registered
in the PROSPERO prospective register of systematic
reviews (CRD42015016761), and any changes to the
study protocol will be registered as amendments with
PROSPERO.
The IPD meta-analysis has been designed and will be
conducted in accordance with best-practice standards as
elaborated in the Cochrane Handbook for Systematic
Reviews of Diagnostic Test Accuracy35 and other key
sources.30 31 36 Results will be reported in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses of individual patient data
(PRISMA-IPD) statement.37 To conduct the meta-
analysis, we will seek primary datasets that allow us to
compare HADS-D scores to MDD or major depressive
episode (MDE) diagnostic status. Most primary studies
use MDD as the reference standard, but some may use
MDE, which is identical with respect to the symptoms of
depression, but does not exclude patients with psychotic
disorders or a history of manic episodes. If both are
available, we will use MDD.
Sources of evidence
Our search strategy, which is based on strategies used in
previous systematic reviews,34 38 was developed by a
medical librarian and peer reviewed by another medical
librarian. MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations, PsycINFO (OvidSP platform)
and Web of Science (Web of Knowledge platform) will
be searched. The MEDLINE search strategy was vali-
dated by testing against already-identiﬁed publications
from preliminary searches. The strategy was then
adapted for PsycINFO and Web of Science. We limited
our search strategy to these databases based on research
showing that adding other databases (eg, EMBASE)
when the MEDLINE search is highly sensitive does not
identify additional eligible studies.39 The Cochrane
Handbook for Systematic Reviews of Diagnostic Test
Accuracy35 suggests combining concepts of the index
test and the target conditions, but this was redundant
for depression screening tools as these tests are limited
to testing for depression. Thus, the search strategy for
electronic databases was composed of two concepts: the
index test of interest and studies of screening accuracy.
There are no published search hedges designed speciﬁc-
ally for mental health screening, but several key articles
were consulted in developing search terms to ensure
retrieval of relevant publications.40–42 Search strategies
use a combination of subject headings, when available in
the database, as well as keywords in the title, abstract or
anywhere else in the record. See online supplementary
ﬁle 1 for detailed information on searches. To supple-
ment electronic searches, reference lists of all included
publications and relevant reviews will be scanned. In
addition, a related articles search will be conducted for
included papers indexed in MEDLINE using the
PubMed ‘related articles’ search feature. We will also
contact researchers who have published on the topic to
obtain information about additional, unpublished
studies. Search results will be initially uploaded into the
citation management database RefWorks (RefWorks,
RefWorks-COS, Bethesda, Maryland, USA), and the
RefWorks duplicate check function will be used to iden-
tify citations retrieved from multiple sources. Unique
citations will then be uploaded into the systematic review
program DistillerSR (Evidence Partners, Ottawa,
Canada), and DistillerSR will be used to store and track
search results and to track results of the review process.
To identify relevant datasets, we will review articles in
any language. Datasets will be sought for inclusion if
patients completed the HADS-D and were assessed for
MDD or MDE using Diagnostic and Statistical Manual of
Mental Disorders, third edition (DSM-III, DSM-IV or
DSM-V) or International Classiﬁcation of Diseases (ICD,
V.10) criteria within 2 weeks (before or after) of comple-
tion of the HADS-D, since major depression criteria are
for symptoms in the last 2 weeks. Diagnostic assessments
must be based on a validated structured or semistruc-
tured interview (eg, Structured Clinical Interview for
DSM,43 Composite International Diagnostic Interview44).
Datasets where some patients were administered the
screening tools within 2 weeks of the diagnostic inter-
view and some patients were not will be included if the
original data allow us to select patients administered the
diagnostic interview and screening tools within the
2-week window. Data from studies where all patients are
known to have psychiatric diagnoses, have been referred
for mental health evaluation or are undergoing treat-
ment for depression will be excluded, with the excep-
tion of patients treated for substance use disorders, for
whom depression screening may be considered. The
coding manual for inclusion and exclusion decisions is
shown in online supplementary ﬁle 2.
Two investigators will independently review titles and
abstracts for eligibility. If either reviewer determines that
a study may be eligible based on title or abstract review,
then a full-text article review will be completed.
Disagreement between reviewers after full-text review
will be resolved by consensus, including a third investiga-
tor as necessary. Translators will be consulted to evaluate
titles/abstracts and articles for languages other than
those for which team members are ﬂuent. See online
supplementary ﬁle 3 for a preliminary PRISMA ﬂow of
studies ﬁgure.
Transfer of data and dataset management
Authors of studies containing datasets that meet inclu-
sion criteria will be contacted to invite them to contrib-
ute primary data for inclusion. Data will only be used
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from studies that received ethics approval and all data
that are transferred will be properly deidentiﬁed prior
to transfer. All IPD that are obtained will be cleaned and
coded to make patient data as uniform as possible across
datasets, then entered into a single database. A prelimin-
ary codebook has been developed for coding data from
original studies of the HADS-D. Actual data coding and
transfer from original studies into the IPD database will
be done by a supervised staff or trainee member of the
team. Patient characteristics and screening accuracy
results for each study using the cleaned datasets will be
compared with those from the original datasets to iden-
tify any potential discrepancies.
In addition to obtaining original patient-level data,
data will also be extracted from the published articles of
included studies. We will crosscheck the published data
with the original patient-level data obtained from each
dataset, and any inconsistencies will be discussed with
the original authors. Corrections will be made as
necessary.
Quality assessment
The Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) tool45 will be used to assess risk of bias
factors in primary studies. QUADAS-2 incorporates
assessments of risk of bias across four core domains:
patient selection, the index test, the reference standard,
and the ﬂow and timing of assessments. Two reviewers
will independently assess risk of bias with any discrepan-
cies resolved by consensus.
Data analysis
Analyses will estimate sensitivity and speciﬁcity, which
will be used to generate estimates of positive and nega-
tive predictive value, which are more useful clinically.
A bivariate random-effects meta-analysis will be ﬁt,
estimated via Gauss-Hermite adaptive quadrature, as
described in Riley et al,46 for the full range of plausible
cut-off values. This approach models sensitivity and spe-
ciﬁcity simultaneously and accounts for variation in
within-study precision.46 Data from all primary studies
will be analysed at the same time using a random-effects
model so that sensitivity and speciﬁcity are assumed to
vary across studies. For each cut-off, separately, this
model will provide us with an overall summary sensitivity
and speciﬁcity and an overall summary diagnostic OR.
We will compare results that only include datasets that
allow the exclusion of patients diagnosed with depres-
sion or receiving depression treatment (including anti-
depressants with reason unspeciﬁed) with results that
also include studies where these data are not available.
Additionally, a subgroup analysis will be conducted that
includes only data from countries listed as ‘very high
development’ on the United Nation’s Human
Development Index.47
Heterogeneity will be quantiﬁed for each cut-off ana-
lysis by reporting the estimated variances of the random
effects for sensitivity and speciﬁcity, as well as by
estimating R. R is the ratio of the estimated SD of the
summary sensitivity (or speciﬁcity) from the
random-effects model to the estimated SD of the
summary sensitivity (or speciﬁcity) from the ﬁxed-effects
model.48 We will explore underlying reasons for hetero-
geneity using patient-level and study-level factors. In
diagnostic accuracy, this can easily be accomplished by
including the factors or interaction terms in the
random-effects model described above.46 These analyses
take advantage of the richness of IPD. When analysed at
the patient level, accounting for correlation between
patients from the same study, and for the correlation
between sensitivity and speciﬁcity via the random-effects
bivariate model, they are more powerful to detect inter-
actions and not vulnerable to ecologic bias compared
with traditional meta-analyses.49–53 At the patient level,
covariates will include age (<60 years vs ≥60 years), sex
and inpatient versus outpatient status. Study-level covari-
ates, including risk of bias factors described in
QUADAS-2,45 will also be evaluated. QUADAS-2 factors
include patient selection factors, blinding of reference
standard to index test results, type of reference standard
(eg, semistructured diagnostic interview, structured diag-
nostic interview) and timing of administration of index
test and reference standard (eg, same day, delay of 1–
7 days, delay of >7 days). Signiﬁcance levels for the pre-
speciﬁed interaction analyses will not be adjusted for
multiple comparisons.
In addition to estimating sensitivity and speciﬁcity for
each relevant cut-off, we will build a predictive model
that uses the score on the screening questionnaire and
any other key factors that account for substantial hetero-
geneity to estimate the probability that a patient has
major depression. The model will be evaluated in terms
of its calibration (eg, slope of linear predictor; are
average, low and high predictions correct?) and discrim-
ination (eg, c-statistic; how well are low-risk subjects dis-
tinguished from high-risk subjects?).54 Validation with
the same subjects used to develop a model results in
overly optimistic performance. Internal validation will be
assessed via the bootstrap method, which is preferable to
split sample validation approaches (eg, developing the
model in half the sample and evaluating it in the other
half).55 Although there are advantages to external valid-
ation, given the wide range of study samples that will be
used, it would be unlikely that there would be another
comparable dataset large enough for validation. Thus,
assessment of internal validity via bootstrapping will help
develop an understanding of how the model will likely
perform in a clinical setting. Furthermore, by using the
regression coefﬁcients adjusted for optimism (ie, the
shrinkage estimates), we will maximise actual accuracy.
On the basis of our pilot work, it is anticipated that
missing data will be minimal for the variables of primary
interest. Regardless, multiple imputation will be done
using chained equations54 56 to impute data for binary
and continuous variables, considering study as a ﬁxed
effect in the imputation model.57 This will allow
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imputation for variables missing for entire studies as well
those missing more sporadically.
Studies included in the IPD meta-analysis will be com-
pared with eligible studies that do not provide data in
terms of sensitivity and speciﬁcity, using published
summary data from the studies that do not provide data.
Depending on the number of missing studies, a sensitiv-
ity analysis may also be conducted that includes aggre-
gate summary estimates of sensitivity and speciﬁcity from
the studies that do not provide IPD in the main
meta-analysis, along with data from studies that contrib-
ute to the IPD meta-analysis.46 If there are a large
number of studies that do not contribute primary data,
this analysis may become the primary analysis.
ETHICS AND DISSEMINATION
This IPD meta-analysis does not require ethics approval,
although only individual studies that obtained ethical
clearance and informed consent will be included. The
reasons that the IPD meta-analysis does not require
ethics review are that the objectives of the IPD
meta-analysis are consistent with the objectives of the
primary studies, which already received ethics approval,
and only anonymised data will be provided by the inves-
tigators of the original studies.
The main outcomes of the IPD meta-analysis reﬂect
knowledge that will inﬂuence future research, clinical
practice and policy. Strategies for effective dissemination
and speciﬁc outputs will be based on research showing
how to best tailor research outputs to different user
groups,58–63 including research on improving the useful-
ness of reports of systematic review and meta-analyses for
healthcare managers and policymakers.61 63
Dissemination will include publication of results in high-
impact medical journals with open access, as well as pre-
sentations in seminars and symposia to policymakers,
healthcare providers and researchers at national and
international conferences.
If the predictive model performs well, we will create
an online calculation tool that will be made freely avail-
able to estimate the probability that a given patient has
major depression based on depression screening results
and key patient characteristics. An example of a tool that
is based on robust research evidence and effectively dis-
seminated is the Fracture Risk Assessment Tool (FRAX)
(http://www.shef.ac.uk/FRAX/index.aspx). The tool
that will be made based on the results of our study will
similarly be presented in an easy-to-use fashion with
tablet and app versions. In addition, simpler nomogram-
based presentations, which are user-friendly graphical
depictions of positive and negative predictive value by
prevalence, will be generated and made available.
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